Clariant delivers robust performance in 2020, successfully mitigating COVID-19 pandemic impacts
11 févr. 2021 01h00 HE
|
Clariant AG
Sales from continuing operations decreased by 5 % in local currency to CHF 3.860 billion EBITDA margin preserved at 15.0 % in a challenging environment compared to a comparable EBITDA margin of 15.7 %...
Delårsrapport 3 2020 januari - september 2020
19 nov. 2020 02h30 HE
|
Northbaze Group AB
Q3 2020 1 juli – 30 september 2020 i korthet Northbaze Group uppnår under det tredje kvartalet en nettoomsättning i nivå med föregående års tredje kvartal med ett positiv EBITDA resultat....
Clariant improves profitability in the first half of 2020 despite a difficult economic environment
30 juil. 2020 01h00 HE
|
Clariant AG
Sales from continuing operations decreased by 5 % in local currency to CHF 1.945 billionEBITDA margin improved to 15.0 % compared to an operational performance of 14.9 % in the first half of 2019 Net...
Delårsrapport 1 2020 januari - mars 2020
28 avr. 2020 02h30 HE
|
Northbaze Group AB
Q1 2020 1 januari – 31 mars 2020 i korthet Northbaze Group ökar sin nettoomsättning med 27 % under årets första kvartal i jämförelse med föregående års första kvartal. Omsättningen inom affärsområdet...
How to Select Office Paper that Impacts Productivity, Profitability in 2020
14 janv. 2020 09h00 HE
|
Boise Paper Holdings LLC
CHICAGO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Office paper may seem like a small expense to many people, but business owners know it can directly impact their productivity and profitability. As small...
Les résultats financiers d'Emerald Health Therapeutics au deuxième trimestre 2019 indiquent un doublement des ventes pour le deuxième trimestre consécutif
30 août 2019 05h10 HE
|
Emerald Health Therapeutics Inc.
VANCOUVER, Colombie-Britannique, 30 août 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (« Emerald ») (TSXV : EMH ; OTCQX : EMHTF) a communiqué aujourd'hui ses résultats financiers...
Emerald Health Therapeutics Reports Second Quarter 2019 Financial Results; Sales Double Second Quarter in a Row
29 août 2019 07h00 HE
|
Emerald Health Therapeutics Inc.
VANCOUVER, British Columbia, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today reported financial results for the quarter ended June 30,...
La coentreprise Pure Sunfarms d'Emerald Health Therapeutics a réalisé un chiffre d'affaires de 32 millions $ au deuxième trimestre, une marge d'EBITDA de 78 %, un coût de production global de 0,65 $/g et un troisième trimestre de rentabilité consécutif
13 août 2019 11h32 HE
|
Emerald Health Therapeutics Inc.
VICTORIA, Colombie-Britannique, 13 août 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (« Emerald ») (TSXV: EMH, OTCQX: EMHTF) a publié des résultats financiers préliminaires non...
Emerald Health Therapeutics’ Pure Sunfarms JV Reaches Q2 Sales of $32 Million, 78% EBITDA Margin, $0.65/Gram All-in Production Cost, and Third Consecutive Quarter of Profitability
13 août 2019 00h19 HE
|
Emerald Health Therapeutics Inc.
VICTORIA, British Columbia, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has provided preliminary, unaudited financial results for the...
Emerald Health Therapeutics Appoints Chief Executive Officer
30 juil. 2019 07h00 HE
|
Emerald Health Therapeutics Inc.
Riaz Bandali has driven innovation, sales, and profitability in a number of global life science companies Emerald also adds Chief Commercial Officer VICTORIA, British Columbia, July 30, 2019 ...